BMS to acquire Mirati and its cancer treatments for $5.8bn

BMS aims to strengthen its pipeline of cancer treatments and will add Mirati's lung cancer medicine to its commercial portfolio.


Read more: BMS to acquire Mirati and its cancer treatments for $5.8bn


https://bit.ly/3tqVtOC